Correspondingly, only 59 (42%) of 140 participant tumours had been identified as PI3K/AKT/PTEN pathway altered,17 which is lower than the proportion detected by other studies.7, 9, 11 In this updated analysis, we did a prespecified exploratory subgroup analysis that used an expanded genetic testing panel to identify participants with PI3K/AKT/PTEN pathway-altered tumours with increased accuracy. This evidence concerns the gene PTEN and neoplasm.